JP2021522825A5 - - Google Patents
Info
- Publication number
- JP2021522825A5 JP2021522825A5 JP2020563545A JP2020563545A JP2021522825A5 JP 2021522825 A5 JP2021522825 A5 JP 2021522825A5 JP 2020563545 A JP2020563545 A JP 2020563545A JP 2020563545 A JP2020563545 A JP 2020563545A JP 2021522825 A5 JP2021522825 A5 JP 2021522825A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- vector
- isolated polypeptide
- nucleic acid
- sgrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670135P | 2018-05-11 | 2018-05-11 | |
| US62/670,135 | 2018-05-11 | ||
| PCT/CA2019/050629 WO2019213776A1 (en) | 2018-05-11 | 2019-05-10 | Crispr/cas9 system and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522825A JP2021522825A (ja) | 2021-09-02 |
| JP2021522825A5 true JP2021522825A5 (enExample) | 2022-05-13 |
Family
ID=68467641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020563545A Pending JP2021522825A (ja) | 2018-05-11 | 2019-05-10 | ＣＲＩＳＰＲ／Ｃａｓ９システムおよびその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12378549B2 (enExample) |
| JP (1) | JP2021522825A (enExample) |
| CA (1) | CA3101949A1 (enExample) |
| WO (1) | WO2019213776A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024518135A (ja) * | 2021-05-16 | 2024-04-24 | ジェンエディットバイオ リミテッド | 標的化核酸濃縮方法、オフターゲット同定方法及び遺伝子編集効率評価方法 |
| GB202109675D0 (en) * | 2021-07-05 | 2021-08-18 | Ucl Business Ltd | Treatment for tyrosine degradation-associated disorders |
| AU2024270764A1 (en) | 2023-05-15 | 2025-12-04 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| WO2025194124A1 (en) * | 2024-03-14 | 2025-09-18 | Tessera Therapeutics, Inc. | Modified st1cas9 guide nucleic acids |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140186843A1 (en) | 2012-12-12 | 2014-07-03 | Massachusetts Institute Of Technology | Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| WO2015089427A1 (en) * | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes |
| JP6793547B2 (ja) * | 2013-12-12 | 2020-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物 |
| CA2969619A1 (en) * | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| IL310721B2 (en) * | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
-
2019
- 2019-05-10 JP JP2020563545A patent/JP2021522825A/ja active Pending
- 2019-05-10 WO PCT/CA2019/050629 patent/WO2019213776A1/en not_active Ceased
- 2019-05-10 CA CA3101949A patent/CA3101949A1/en active Pending
- 2019-05-10 US US17/054,008 patent/US12378549B2/en active Active